Full text
Earnings transcript
Read the complete earnings call transcript.
IBRX
ImmunityBio, Inc.
$7.25
0.08
(1.12%)
| Exchange: | NASDAQ |
| Market Cap: | 7.593B |
| Shares Outstanding: | 797105 |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Richard Gerald Adcock | |||||
| Full Time Employees: | 671 | |||||
| Address: |
| |||||
| Website: | https://immunitybio.com |
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 622 | 14,745 | 113,288 |
| Gross Profit | 622 | 14,745 | 112,535 |
| EBITDA | -478,663 | -264,433 | -223,557 |
| Operating Income | -362,250 | -344,182 | -256,027 |
| Net Income | -583,196 | -413,564 | -351,398 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 504,452 | 382,933 | 501,898 |
| Total Liabilities | 1,090,389 | 871,062 | 1,001,472 |
| Total Stockholders Equity | -586,987 | -488,129 | -499,574 |
| Total Debt | 726,723 | 42,289 | 40,982 |
| Cash and Cash Equivalents | 265,453 | 143,428 | 88,334 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -366,757 | -391,236 | -304,936 |
| Capital Expenditure | -30,584 | -6,888 | 0 |
| Free Cash Flow | -397,341 | -398,124 | -304,936 |
| Net Income | -583,196 | -413,645 | 0 |
| Net Change in Cash | 160,822 | -121,875 | -54,481 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,640,891.328 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 3,437,740.782 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 2,419,350 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -3,437,740.782 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -1,640,891.328 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -2,419,350 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 679,567.189 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 1,807,494.002 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 1,168,226.011 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 260,541,364.910 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 545,845,821.881 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 384,145,336.403 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 1.270 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 1.960 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.740 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Growth: Analysis of income statements indicates consistent revenue increases over recent periods, reflecting strong top-line performance. This growth aligns with industry trends in the [industryName] sector, suggesting IBRX is capitalizing on market demand.
- Positive Operating Cash Flow: Cash flow statements show sustained net cash provided by operating activities, indicating operational efficiency and the ability to fund ongoing expenses without excessive reliance on external financing.
- Innovative Product Portfolio: Insights from earnings call transcripts and company descriptions highlight IBRX’s focus on innovation within [product_category] segments, positioning the company as a potential leader in niche markets.
- Strong Market Position: With a market capitalization of [mktCap] and a presence in [sectorName], IBRX demonstrates a competitive stance relative to peers, supported by a solid employee base of [fullTimeEmployees].
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about IBRX valuation
Is ImmunityBio, Inc. (IBRX) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for ImmunityBio, Inc. (IBRX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is IBRX a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether IBRX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is IBRX’s P/E ratio?
You can see IBRX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for IBRX?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is IBRX a good long-term investment?
Whether IBRX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
IBRX
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.12
Trading Metrics:
| Open: | 7.29 | Previous Close: | 7.17 | |
| Day Low: | 6.92 | Day High: | 7.44 | |
| Year Low: | 1.95 | Year High: | 12.43 | |
| Price Avg 50: | 7.56 | Price Avg 200: | 4.94 | |
| Volume: | 12.44M | Average Volume: | 17.542M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeIBRX full analysis
Welcome to MARKETSNAP’s SWOT analysis for IBRX, also known as ImmunityBio, Inc. If you’re a long-term investor looking to dig into the potential of innovative biotech stocks, you’re in the right place. Today, we’re breaking down ImmunityBio, a company in the biotechnology industry within the broader healthcare sector, focused on developing cutting-edge therapies to combat cancer and infectious diseases. Let’s dive into what makes this company tick, explore some recent developments, and analyze its strengths, weaknesses, opportunities, and threats—all with…
